Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) antibody

Antigen: Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2)

Synonyms: PDJ, PRKN, AR-JP, LPRS2, SD01679, dpk, Dmel\CG10523, CG10523, Park, Prkn, zgc:112390, PARK2, pdr-1, LOC100150461

Clonality: Monoclonal (1H4)

Host: Mouse

Reactivity: Human

Conjugate: Un-conjugated

Application: ELISA, Immunofluorescence (IF), Western Blotting (WB)

Certificates: ISO 9001:2008

Catalog no.: ABIN393540

Additional Information

Alternative name: PARK2

Gene ID: 5071

Immunogen: PARK2 (AAH22014, 288 a.a. ~ 388 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 K

Isotype: IgG3 kappa

Clone: 1H4

Description: Other names: ARJP, PDJ, PRKNParkinson disease (autosomal recessive, juvenile) 2, parkin

Characteristics: Purified Mouse Monoclonal Antibody (Mab)

Specificity: PARK2 (AAH22014, 288 a.a. ~ 388 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Molecular Weight: 51641 DA

Comments:

Background: The precise function of this gene is unknown, however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support.

Application Details

Application Notes: ELISA ~~ 1ug/ml~3ng/ml Western blot ~~ 1:500~1000 Immunofluorescence

Concentration: 0.25mg/ml

Purification: Purified

Buffer: Clear, colorless solution in phosphate buffered saline, pH 7.2 .

Storage: Maintain refrigerated at 2-8 deg C for up to 6 months. For long term storage store at -20 deg C in small aliquots to prevent freeze-thaw cycles

Research Area: Ubiquitin-related antibodies, Protein Modifications, Cell Structure

Restrictions: For Research Use only

Images

Immunofluorescence of monoclonal antibody to PARK2 ( Cat# AT3182a ) on HeLa cell . [antibody concentration 10 ug/ml] PARK2 monoclonal antibody (M01), clone 1H4 Western Blot analysis of PARK2 expression in Jurkat ( Cat # L017V1 ).

anti-Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) antibody (Image 2)

Publications

Product: Suen, Narendra, Tanaka et al.: "Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, Issue 26, pp. 11835-40, 2010 (PubMed).

Marder, Tang, Mejia-Santana et al.: "Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study." in: Archives of neurology, Vol. 67, Issue 6, pp. 731-8, 2010 (PubMed).

Prabhakar, Vinish, Das et al.: "Occurrence of PARK2 mutations in a never-smoker population with Parkinson's disease in North India." in: Neuroepidemiology, Vol. 35, Issue 2, pp. 152-9, 2010 (PubMed).

Bailey, Xie, Do et al.: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, 2010 (PubMed).

Kägi, Klein, Wood et al.: "Nonmotor symptoms in Parkin gene-related parkinsonism." in: Movement disorders : official journal of the Movement Disorder Society, Vol. 25, Issue 9, pp. 1279-84, 2010 (PubMed).